(2,5-dioxopyrrolidin-1-yl) 4-[(6S)-2-acetyl-9-azabicyclo[4.2.1]non-2-en-9-yl]butanoate
C18H24N2O5 — CID 139445196
Data last refreshed: (MolForge compound catalog, from PubChem)
About (2,5-dioxopyrrolidin-1-yl) 4-[(6S)-2-acetyl-9-azabicyclo[4.2.1]non-2-en-9-yl]butanoate
(2,5-dioxopyrrolidin-1-yl) 4-[(6S)-2-acetyl-9-azabicyclo[4.2.1]non-2-en-9-yl]butanoate (PubChem CID 139445196) has the molecular formula C18H24N2O5 and a molecular weight of 348.40 g/mol. Its IUPAC name is (2,5-dioxopyrrolidin-1-yl) 4-[(6S)-2-acetyl-9-azabicyclo[4.2.1]non-2-en-9-yl]butanoate.
Molecular Properties
| Compound Name | (2,5-dioxopyrrolidin-1-yl) 4-[(6S)-2-acetyl-9-azabicyclo[4.2.1]non-2-en-9-yl]butanoate |
|---|---|
| PubChem CID | 139445196 |
| Molecular Formula | C18H24N2O5 |
| Molecular Weight | 348.40 g/mol |
| Exact Mass | 348.17 |
| IUPAC Name | (2,5-dioxopyrrolidin-1-yl) 4-[(6S)-2-acetyl-9-azabicyclo[4.2.1]non-2-en-9-yl]butanoate |
| SMILES | CC(=O)C1=CCC[C@H]2CCC1N2CCCC(=O)ON1C(=O)CCC1=O |
| InChI | InChI=1S/C18H24N2O5/c1-12(21)14-5-2-4-13-7-8-15(14)19(13)11-3-6-18(24)25-20-16(22)9-10-17(20)23/h5,13,15H,2-4,6-11H2,1H3/t13-,15?/m0/s1 |
| InChIKey | SJEHLTCYTPBIKM-CFMCSPIPSA-N |
| XLogP | 1.52 |
| TPSA | 83.99 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 25 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 348.40 |
| LogP ≤ 5 | 1.52 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'phthalimide', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 139445196 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.